retatrutide fda approval status as of october 2025 This weight-loss drug hasn't been approved by the FDA. Doctors are prescribing it anyway Covering Every FDA Oncology Approval
Description
Problem: you're never hungry

Brand-name Wegovy and Zepbound are sometimes covered for patients with documented obesity (BMI 30+) or BMI 27+ with a comorbid condition

While semaglutide itself does not appear to directly promote kidney stone formation through its mechanism of action, patients experiencing significant gastrointestinal symptoms or rapid weight loss may face increased risk if adequate hydration is not maintained

We also offer premium prescription supplements to manage side effects and optimize your GLP-1 program

Need products with established regulatory oversight

Some people may experience more pronounced effects than what clinical averages suggest
